Acadia Pharmaceuticals said Monday that U.S. regulators had rejected its application seeking to expand the use of its anti-psychosis drug Nuplazid to a broader group of patients.
The decision by the Food and Drug Administration was widely expected following a March 8 letter sent by the agency to Acadia, citing undefined “deficiencies” in the Nuplazid application.
About the Author Reprints
